All OTX-201 articles

News

Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn

2025-10-14T09:59:35Z

Gains access to OTX-201, a preclinical CAR T therapy being developed to treat autoimmune diseases.